Divergence of brain prostaglandin H synthase activity and oxidative damage in mice with encephalitis

Journal of Neuropathology and Experimental Neurology

Volumn 58, Issue 12, 1999, Pages 1269-1275

  Valyi Nagy, Tibor ^b   Sidell, Kathrin R ^c   Marnett, Lawrence J ^a,b   Roberts II, L Jackson ^b   Dermody, Terence S ^a,b   Morrow, Jason D ^b   Montine, Thomas J ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c NONE

Author keywords

Alzheimer disease; Encephalitis; Oxidative damage; Prostaglandin H synthase activity; Reovirus

Indexed keywords

4 HYDROXYNONENAL; BIOLOGICAL MARKER; ISOPROSTANE; PROSTAGLANDIN F2; PROSTAGLANDIN SYNTHASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; INFLAMMATORY INFILTRATE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REOVIRUS; SIGNAL TRANSDUCTION; VIRUS ENCEPHALITIS;

EID: 0032763126     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199912000-00008     Document Type: Article

References (46)

1. Griffin WS, Sheng JG, Royston MC, et al. Glial-neuronal interactions in Alzheimer's disease: The potential role of a 'cytokine cycle' in disease progression. Brain Pathol 1998;8:65-72
2. McGeer PL, Schulzer M, McGeer E. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiological studies. Neurology 1996;47: 425-32
3. Boyd JA. Prostaglandin H Synthase. Meth Enzymol 1990;186: 283-87
4. Lukiw WJ, Bazan NG. Cyclooxygenase 2 RNA message abundance, stability, and hypervariablity in sporadic Alzheimer's neocortex. J Neurosci Res 1997;50:937-45
5. Kaufmann WE, Andreasson KI, Isakson PC, Worley PE Cyclooxygenases and the central nervous system. Prostaglandins 1997;54: 601-24
6. Pasinetti GM. Cyclooxygenase and inflammation in Alzheimer's disease: Experimental approaches and clinical interventions. J Neurosci Res 1998;54:1-6
7. Chang JW, Coleman PD, O'Banion MK. Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease. Neurobiol Aging 1996;17:801-8
8. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998;87:319-24
9. Marchceselli VL, Bazan NG. Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. J Biol Chem 1996;271:24794-99
10. 2 levels in patients with probable Alzheimer's disease. Neurology 1999 (in press)
11. Wong PT, McGeer PL, McGeer EG. Decreased prostaglandin synthesis in postmortem cerebral cortex from patient's with Alzheimer's disease. Neurochem Int 1992;21:197-202
12. Markesbery WR, Carney JM. Oxidative alterations in Alzheimer's disease. Brain Pathology 1999;9:133-46
13. Montine KS, Olson SJ, Amarnath V, Whetsell WO, Graham DG, Montine TJ. Immunochemical detection of 4-hydroxynonenal adducts in Alzheimer's disease is associated with APOE4. Am J Pathol 1997;150:437-43
14. Montine KS, Kim PJ, Olson SJ, Markesbery WR, Montine TJ. 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 1997;56:866-71
15. Montine K, Reich E, Olson SJ, Markesbery WR, Montine T. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer's disease is associated with APOE genotype. J Neuropathol Exp Neurol 1998;57:415-25
16. Sayre LM, Zelasko DA, Harris PLR, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer disease. J Neurochem 1997;2092-97
17. Smith MA, Sayre LM, Anderson VE, et al. Cytochemical demonstration of oxidative damage in Alzheimer's disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J Histochem Cytochem 1998;46:731-35
18. 2-isoprostanes are increased in Alzheimer's disease. Ann Neurol 1998;44:410-13
19. 2-isoprostane concentration in probable Alzheimer's disease. Neurology 1999;52:562-65
20. Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ, Morrow JD. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles, or with APOE genotype in Alzheimer's disease patients. Am J Pathol 1999;155:863-68
21. Nourooz-Zadeh J, Liu EH, Yhlen B, Anggard EE, Halliwell B. F4-isoprostanes as specific marker of docosahexaenoic acid production in Alzheimer's disease. J Neurochem 1999;72:734-40
22. 2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo. FASEB J 1998;12:1777-84
23. Morrow JD, Roberts LJ. The isoprostanes: Unique bioactive products of lipid peroxidation. Prog Lipid Res 1997;36:1-21
24. Roberts LJ, Morrow JD. Isoprostanes. Novel markers of endogenous lipid peroxidation and potential mediators of oxidant injury. Ann NY Acad Sci 1994;744:237-42
25. Roberts LJ, Montine TJ, Markesbery WR, et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998;273:13605-12
26. Pratico D, Barry OP, Lawson JA, et al. IPF2-alpha-I - an index of lipid peroxidation in humans. Proc Natl Acad Sci 1998;95: 3449-54
27. Montine T, Montine K, Olson SJ, et al. Increased cerebral cortical lipid peroxidation and abnormal phospholipids in aged homozygous apoE-deficient C57BL/6J mice. Exp Neurol 1999;158:234-41
28. Dermody TS, Nibert ML, Wetzel JD, Tong X, Fields BN. Cells and viruses with mutations affecting viral entry are selected during persistent infections of L cells with mammalian reoviruses. J Virol 1993;67:2055-63
29. Virgin HW, Basel-Duby R, Fields BN, Tyler KL. Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing). J Virol 1988;62:4594-4604
30. Wetzel JD, Chappell JD, Fogo AB, Dermody TS. Efficiency of viral entry determines the capacity of murine erythroleukemia cells to support persistent infections by mammalian reovirus. J Virol 1997;71:299-306
31. Morrow JD, Robertsll LJ. Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical catalyzed mechanism. Meth Enzymol 1994;233:163-74
32. Esiri MM, Hyman BT, Beyreuther K, Masters C. Ageing and dementia. In: Graham DI, Lantos PL, eds. Greenfield's neuropathology. 6 ed. London: Arnold, 1997:153-234
33. Margolis G, Kilham L, Gonatos N. Reovirus type III encephalitis: Observations of virus-cell interactions in neural tissues. I. Light microscopy studies. Lab Invest 1971;24:91-109
34. Spriggs DR, Bronson RT, Fields BN. Hemagglutinin variants of reovirus type 3 have altered central nervous system tropism. Science 1983;220:505-7
35. Tyler KL, Fields BN, Reoviruses. In: Fields BN, Knipe DM, Howley PM, eds. Fields's virology. Philadelphia: Lippincott-Raven, 1996:1597-623
36. Oberhaus SM, Smith RL, Clayton GH, Dermody TS, Tyler KL. Reovirus infection and tissue injury in the mouse central nervous system are associated with apoptosis. J Virol 1996;71:2100-106
37. Siedlik PH, Marnett LJ. Oxidizing radical generation by prostaglandin H synthase. Meth Enzymol 1984;105:412-16
38. Amarnath V, Valentine WM, Montine TJ, et al. Reactions of 4-hydroxy-2(E)-nonenal and related aldehydes with proteins studied by carbon-13 nuclear magnetic resonance spectroscopy. Chem Res Toxicol 1998;11:317-28
39. Love S, Jenner P. Oxidative stress in neurological disease. Brain Pathol 1999;9:55-56
40. Marcus DL, Rodriguez TC, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 1998;150:40-44
41. McIntosh LJ, Trush MA, Troncoso JC. Increased susceptibility of Alzheimer's disease temporal cortex to oxygen free radical-mediated processes. Free Rad Biol Med 1997;23:183-90
42. Lazarewicz JW, Salinska E. N-methyl-D-aspartate-evoked release of cyclooxygenase products in rabbit hippocampus: An in vivo microdialysis study. J Neurochem Res 1995;40:660-66
43. Slepko N, Levi G. Progressive activation of adult microglial cells in vitro. GLIA 1996;16:241-46
44. Kolko M, DeCoster A, RodriguezdeTurco EB, Bazan NG. Synergy by secretory phospholipase A2 and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures. J Biol Chem 1996;271:32722-28
45. Lee RK, Knapp S, Wurtman RJ. Prostaglandin E2 stimulates amyloid precursor protein gene expression: Inhibition by immunosuppressants. J Neurosci 1999;19:940-47
46. 2 induced polymerization of human alpha-1-antichymotrypsin and suppressed its protease inhibitory activity: Implications for Alzheimer's disease. Biochem Biophys Res Comm 1998;249:182-86